RxDoctor Payments Data

Marcie Nicks, NP

Family · Watkinsville, GANPI 1215388871

Payments from drug & device makers

$2,469in general payments, 2019–2025

Across 102 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$467
  • Medtronic$357
  • Sumitomo Pharma America, Inc.$299
  • AbbVie$260
  • Coloplast$132
  • Boston Scientific$90
  • plus $863 from 22 others

What the payments were for

  • Food & beverage$2,38497%
  • Education$853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,469 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$39,067
Medicare patients
234
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron94$67,549
MyrbetriqMirabegron48$26,345
PremarinEstrogens, Conjugated39$12,644
Estradiol170$10,708
Climara ProEstradiol/Levonorgestrel12$3,021
Estradiol (Twice Weekly)Estradiol29$1,978
Methenamine Hippurate30$1,761
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst39$420
Oxybutynin Chloride ErOxybutynin Chloride18$384
ProgesteroneProgesterone, Micronized11$338
Clobetasol Propionate15$326
Solifenacin Succinate15$292
NitrofurantoinNitrofurantoin Macrocrystal13$260
Metronidazole35$218
Nystatin25$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$299$67,54994 claims
Astellas Pharma US IncMyrbetriq$467$26,34548 claims
PfizerPremarin$33$12,64439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →